Higher rate of BRAF mutation in papillary thyroid cancer over time: A single-institution study

Aarti Mathur, Willeford Moses, Reza Rahbari, Elham Khanafshar, Quan Yang Duh, Orlo Clark, Electron Kebebew

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The incidence of thyroid cancer has doubled over the past decade. The reason for this dramatic increase in incidence is controversial. Some investigators have suggested that the increased incidence is because of increased detection of small primary tumors as a result of diagnostic scrutiny. Conversely, some investigators have demonstrated an increased incidence across all tumor sizes, suggesting that other factors may play a role. This study was undertaken to investigate the clinical, pathologic, and molecular changes present in papillary thyroid cancer over a 15-year period during which the incidence of papillary thyroid cancer doubled. METHODS: A total of 628 patients with conventional papillary thyroid cancer and 228 tumor samples from a single institution were analyzed from 1991 to 2005. Time-trend analyses of demographic, clinical, pathologic, and tumor genotype were performed over three 5-year time periods: group I (1991-1995), group II (1996-2000), and group III (2001-2005). RESULTS: The authors found no differences in age, sex, ethnicity, primary tumor size, rate of extrathyroidal invasion, or overall TNM cancer stage among the 3 time groups. The rate of BRAF V600E mutation was significantly higher in group III (88% BRAF V600E positive) as compared with groups I and II (51% and 43%, respectively) (P

Original languageEnglish (US)
Pages (from-to)4390-4395
Number of pages6
JournalCancer
Volume117
Issue number19
DOIs
StatePublished - Oct 1 2011
Externally publishedYes

Fingerprint

Mutation Rate
Incidence
Neoplasms
Research Personnel
Thyroid Neoplasms
Papillary Thyroid cancer
Genotype
Demography
Mutation

Keywords

  • incidence
  • molecular changes
  • prevalence
  • somatic mutations
  • thyroid cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mathur, A., Moses, W., Rahbari, R., Khanafshar, E., Duh, Q. Y., Clark, O., & Kebebew, E. (2011). Higher rate of BRAF mutation in papillary thyroid cancer over time: A single-institution study. Cancer, 117(19), 4390-4395. https://doi.org/10.1002/cncr.26072

Higher rate of BRAF mutation in papillary thyroid cancer over time : A single-institution study. / Mathur, Aarti; Moses, Willeford; Rahbari, Reza; Khanafshar, Elham; Duh, Quan Yang; Clark, Orlo; Kebebew, Electron.

In: Cancer, Vol. 117, No. 19, 01.10.2011, p. 4390-4395.

Research output: Contribution to journalArticle

Mathur, A, Moses, W, Rahbari, R, Khanafshar, E, Duh, QY, Clark, O & Kebebew, E 2011, 'Higher rate of BRAF mutation in papillary thyroid cancer over time: A single-institution study', Cancer, vol. 117, no. 19, pp. 4390-4395. https://doi.org/10.1002/cncr.26072
Mathur, Aarti ; Moses, Willeford ; Rahbari, Reza ; Khanafshar, Elham ; Duh, Quan Yang ; Clark, Orlo ; Kebebew, Electron. / Higher rate of BRAF mutation in papillary thyroid cancer over time : A single-institution study. In: Cancer. 2011 ; Vol. 117, No. 19. pp. 4390-4395.
@article{1a552000424545938387f05d0cec62d9,
title = "Higher rate of BRAF mutation in papillary thyroid cancer over time: A single-institution study",
abstract = "BACKGROUND: The incidence of thyroid cancer has doubled over the past decade. The reason for this dramatic increase in incidence is controversial. Some investigators have suggested that the increased incidence is because of increased detection of small primary tumors as a result of diagnostic scrutiny. Conversely, some investigators have demonstrated an increased incidence across all tumor sizes, suggesting that other factors may play a role. This study was undertaken to investigate the clinical, pathologic, and molecular changes present in papillary thyroid cancer over a 15-year period during which the incidence of papillary thyroid cancer doubled. METHODS: A total of 628 patients with conventional papillary thyroid cancer and 228 tumor samples from a single institution were analyzed from 1991 to 2005. Time-trend analyses of demographic, clinical, pathologic, and tumor genotype were performed over three 5-year time periods: group I (1991-1995), group II (1996-2000), and group III (2001-2005). RESULTS: The authors found no differences in age, sex, ethnicity, primary tumor size, rate of extrathyroidal invasion, or overall TNM cancer stage among the 3 time groups. The rate of BRAF V600E mutation was significantly higher in group III (88{\%} BRAF V600E positive) as compared with groups I and II (51{\%} and 43{\%}, respectively) (P",
keywords = "incidence, molecular changes, prevalence, somatic mutations, thyroid cancer",
author = "Aarti Mathur and Willeford Moses and Reza Rahbari and Elham Khanafshar and Duh, {Quan Yang} and Orlo Clark and Electron Kebebew",
year = "2011",
month = "10",
day = "1",
doi = "10.1002/cncr.26072",
language = "English (US)",
volume = "117",
pages = "4390--4395",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "19",

}

TY - JOUR

T1 - Higher rate of BRAF mutation in papillary thyroid cancer over time

T2 - A single-institution study

AU - Mathur, Aarti

AU - Moses, Willeford

AU - Rahbari, Reza

AU - Khanafshar, Elham

AU - Duh, Quan Yang

AU - Clark, Orlo

AU - Kebebew, Electron

PY - 2011/10/1

Y1 - 2011/10/1

N2 - BACKGROUND: The incidence of thyroid cancer has doubled over the past decade. The reason for this dramatic increase in incidence is controversial. Some investigators have suggested that the increased incidence is because of increased detection of small primary tumors as a result of diagnostic scrutiny. Conversely, some investigators have demonstrated an increased incidence across all tumor sizes, suggesting that other factors may play a role. This study was undertaken to investigate the clinical, pathologic, and molecular changes present in papillary thyroid cancer over a 15-year period during which the incidence of papillary thyroid cancer doubled. METHODS: A total of 628 patients with conventional papillary thyroid cancer and 228 tumor samples from a single institution were analyzed from 1991 to 2005. Time-trend analyses of demographic, clinical, pathologic, and tumor genotype were performed over three 5-year time periods: group I (1991-1995), group II (1996-2000), and group III (2001-2005). RESULTS: The authors found no differences in age, sex, ethnicity, primary tumor size, rate of extrathyroidal invasion, or overall TNM cancer stage among the 3 time groups. The rate of BRAF V600E mutation was significantly higher in group III (88% BRAF V600E positive) as compared with groups I and II (51% and 43%, respectively) (P

AB - BACKGROUND: The incidence of thyroid cancer has doubled over the past decade. The reason for this dramatic increase in incidence is controversial. Some investigators have suggested that the increased incidence is because of increased detection of small primary tumors as a result of diagnostic scrutiny. Conversely, some investigators have demonstrated an increased incidence across all tumor sizes, suggesting that other factors may play a role. This study was undertaken to investigate the clinical, pathologic, and molecular changes present in papillary thyroid cancer over a 15-year period during which the incidence of papillary thyroid cancer doubled. METHODS: A total of 628 patients with conventional papillary thyroid cancer and 228 tumor samples from a single institution were analyzed from 1991 to 2005. Time-trend analyses of demographic, clinical, pathologic, and tumor genotype were performed over three 5-year time periods: group I (1991-1995), group II (1996-2000), and group III (2001-2005). RESULTS: The authors found no differences in age, sex, ethnicity, primary tumor size, rate of extrathyroidal invasion, or overall TNM cancer stage among the 3 time groups. The rate of BRAF V600E mutation was significantly higher in group III (88% BRAF V600E positive) as compared with groups I and II (51% and 43%, respectively) (P

KW - incidence

KW - molecular changes

KW - prevalence

KW - somatic mutations

KW - thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=80052944896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052944896&partnerID=8YFLogxK

U2 - 10.1002/cncr.26072

DO - 10.1002/cncr.26072

M3 - Article

C2 - 21412762

AN - SCOPUS:80052944896

VL - 117

SP - 4390

EP - 4395

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 19

ER -